Elotuzumab (trade name: Empliciti) has been approved in Germany since May 2016 for the treatment of multiple myeloma. The drug is an option for adult patients who have already had treatment at least once. It is combined with the drugs lenalidomide and dexamethasone.
Multiple myeloma is a rare type of cancer in which mutated plasma cells multiply uncontrollably in the bone marrow. If the disease progresses, the bone is destroyed and normal blood formation becomes impossible. This can cause bone pain and bone fractures as well as anemia. In addition, multiple myeloma weakens the immune system, making it a life-threatening disease.
The new drug aims to stimulate the immune system to attack the tumor cells.
Elotuzumab is given as an infusion in combination with dexamethasone and lenalidomide in 28-day cycles. During the first two cycles, patients receive one infusion per week. After that the drug is given every two weeks.
The standard treatment option for people with multiple myeloma is the drug bortezomib. It can be combined with doxorubicin or dexamethasone. Lenalidomide combined with dexamethasone may also be an option.
In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to find out whether elotuzumab has any advantages or disadvantages for people with multiple myeloma when compared with the current standard treatments.
However, the manufacturer did not provide any suitable data with which to do the assessment.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of elotuzumab (Empliciti).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Elotuzumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment A16-32. Cologne: IQWiG. August 29, 2016.
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.